Ralph Loren, a Boston-based partner in Edwards Wildman's
intellectual property practice, discussed how Roche has declined to pursue a patent application for a breast cancer drug in the Indian market in World Intellectual Property Review. In the article, "Roche Relinquishes Patent on Breast Cancer Drug in India
," Loren said, "This was not an application for the underlying drug, it was a secondary patent that was adding to the original. If it were for a patent that underlies the finer details of a drug, that’s worth fighting but purely an add on would not." Loren added, "They [Roche] would have looked at this and thought, how much is it worth fighting? India is not a good environment for pharmaceuticals at the moment and at some point, there will be a cheaper version on the market. Roche would have thought they did not want to spend a huge amount of money on something they would be likely to lose."